BION-1301

DRUG3 trials

Sponsors

Chinook Therapeutics, Inc., Novartis Pharmaceuticals

Conditions

Healthy VolunteerIgA NephropathyImmunoglobulin A NephropathyMultiple Myeloma

Phase 1

Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)

TerminatedNCT03340883

Chinook Therapeutics, Inc.Multiple Myeloma

Start: 2017-11-15End: 2019-07-09Updated: 2021-04-01

Open-label Safety and PK Study of BION-1301 in Japanese Healthy Subjects

CompletedNCT05508204

Chinook Therapeutics, Inc.Healthy Volunteer

Start: 2022-07-19End: 2022-12-16Updated: 2023-01-11

Phase 3

A Study of Zigakibart in Adults With IgA Nephropathy

Active, not recruitingNCT05852938

Novartis PharmaceuticalsIgA Nephropathy, Immunoglobulin A Nephropathy

Start: 2023-07-06End: 2028-01-25Updated: 2026-04-01

Related Papers

Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis.

2025-06-101 citations

Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy

Kidney International2025-06-0510 citations

Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.

Journal of Clinical Oncology2019-05-2010 citations

Pharmacokinetics, pharmacodynamics, safety, and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.

Journal of Clinical Oncology2019-05-20

APRIL Is Significantly Elevated at All Stages of Multiple Myeloma (MM) and Interferes with Anti-Bcma Monoclonal Antibody-Mediated Cytolysis, Supporting the Clinical Evaluation of Bion-1301 As a Novel Therapeutic Approach in MM

Blood2018-11-295 citations